Home > Boards > US OTC > Medical - Drugs > Regenex Biopharmaceuticals (RGRX)

RegeneRx's TB4 Shown to Significantly Limit Brain Damage

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
SPM555 Member Profile
 
Followed By 129
Posts 4,711
Boards Moderated 1
Alias Born 08/01/09
160x600 placeholder
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/17/2019 4:10:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:10:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:08:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:08:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:07:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:06:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:06:14 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/16/2019 4:19:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 4:18:14 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/16/2019 11:22:09 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/16/2019 11:21:04 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:20:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:20:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:20:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:19:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:19:13 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:08:59 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 4/3/2019 6:03:22 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 4/3/2019 6:03:22 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/29/2019 4:14:22 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 3/7/2019 2:15:15 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 3/6/2019 6:03:03 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 3/6/2019 6:02:39 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/5/2019 4:56:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/1/2019 4:50:48 PM
SPM555   Tuesday, 10/20/15 10:41:13 AM
Re: None
Post # of 223 
RegeneRx's TB4 Shown to Significantly Limit Brain Damage After Stroke by Upregulating microRNA-200a PR Newswire   "Press Releases US - English"

ROCKVILLE, Md. , Oct. 20, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a new scientific publication in the most recent issue of the Journal of Neurochemistry describing how Thymosin beta 4 (TB4) reduces neurological injury following a stroke by up-regulating the expression of microRNA-200a (miR-200a).

The authors found that miR-200a, a very short and specific piece of RNA, is increased in the presence of TB4 in an in vitro stroke model, as well as when TB4 is administered systemically ina similarmodel. This increased miR-200a results in the down-regulation of a number of proteins that can negatively affect the repair of damaged tissue, in this case central nervous system tissue around the area damaged by the stroke.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist